Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities

References

• World Health Organization. Vaccines against influenza WHo position paper – November 2012. Wkly Epidemiol Rec. 2012;87:461–476.
   PubMedGoogle Scholar
• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–1300. doi: 10.1016/S0140-6736(17)33293-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Review of global influenza activity, October 2016– October 2017. Wkly Epidemiol Rec. 2017;92:761–780.
   PubMedGoogle Scholar
• Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263. doi: 10.1016/j.ejpb.2015.05.023
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Wkly Epidemiol Rec. 2018;93:133–152.
   PubMedGoogle Scholar
• Hussain A, Ali S, Ahmed M, et al. The anti-vaccination movement: a regression in modern medicine. Cureus. 2018;10:e2919.
   PubMed Web of Science ®Google Scholar
• Frieden TR, Harold Jaffe DW, Director for Science James Stephens AW, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the advisory committee on immunization practices (ACIP), centers for disease control and prevention. MMWR 2011; 6060. , [cited 2019 Feb 25]. Available from: http://www.cdc.gov/flu.
   Google Scholar
• Ison MG. Antiviral treatments. Clin Chest Med. 2017;38:139–153. doi: 10.1016/j.ccm.2016.11.008
   PubMed Web of Science ®Google Scholar
• Leneva IA, Burtseva EI, Yatsyshina SB, et al. Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010–2011 influenza season in Russia. Int J Infect Dis. 2016;43:77–84. doi: 10.1016/j.ijid.2016.01.001
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923. doi: 10.1056/NEJMoa1716197
   PubMed Web of Science ®Google Scholar
• Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170–177. doi: 10.1016/j.antiviral.2016.06.007
   PubMed Web of Science ®Google Scholar
• Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother. 2009;64:1–4. doi: 10.1093/jac/dkp161
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451. doi: 10.1056/NEJMct061675
   PubMed Web of Science ®Google Scholar
• Díaz MO, Pomykala HM, Bohlander SK, et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 1994;22:540–552. doi: 10.1006/geno.1994.1427
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-Specific recognition of single-Stranded RNA via Toll-like receptor 7 and 8. Proc Natl Acad Sci USA. 2013;303:1526–1529.
   Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–384. doi: 10.1038/ni.1863
   PubMed Web of Science ®Google Scholar
• Kim N, Now H, Nguyen NTH, et al. Multilayered regulations of RIG-I in the anti-viral signaling pathway. J Microbiol. 2016;54:583–587. doi: 10.1007/s12275-016-6322-2
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr LM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins downloaded from. 1994. [cited 2019 Mar 14]. Available from: http://science.sciencemag.org/.
   Google Scholar
• Song J, Li S, Zhou Y, et al. Different antiviral effects of IFNα subtypes in a mouse model of HBV infection. Sci Rep. 2017;7:334. doi: 10.1038/s41598-017-00469-1
   PubMed Web of Science ®Google Scholar
• Matzinger SR, Carroll TD, Fritts L, et al. Exogenous ifn-alpha administration reduces influenza a virus replication in the lower respiratory tract of rhesus macaques. PLoS One. 2011;6:e29255, doi:10.1371/journal.pone.0029255.
   PubMed Web of Science ®Google Scholar
• Matzinger SR, Ma Z-M, Miller CJ, et al. Myxovirus resistance gene a (MxA) expression suppresses influenza a virus replication in alpha interferon-treated primate cells. J Virol. 2013;87:1150–1158. doi: 10.1128/JVI.02271-12
   PubMed Web of Science ®Google Scholar
• Arimori Y, Nakamura R, Yamada H, et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013;99:230–237. doi: 10.1016/j.antiviral.2013.05.007
   PubMed Web of Science ®Google Scholar
• Kugel D, Kochs G, Obojes K, et al. Intranasal administration of alpha interferon reduces seasonal influenza a virus morbidity in ferrets. J Virol. 2009;83:3843–3851. doi: 10.1128/JVI.02453-08
   PubMed Web of Science ®Google Scholar
• Hayden FG, Gwaltney JM. Intranasal interferon- 2, treatment of experimental Rhinoviral Colds. J Infect Dis. 1984;150:174–180. doi: 10.1093/infdis/150.2.174
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Betts RF, Erb SM, et al. Intranasally administered interferon as prophylaxis against experimentally induced influenza a virus infection in humans. J Infect Dis. 1987;156:379–383. doi: 10.1093/infdis/156.2.379
   PubMed Web of Science ®Google Scholar
• Sarno TC, Greenberg SB, Couch RB, et al. Efficacy and tolerance of intranasally applied recombinant leukocyte a interferon in normal volunteers. J Infect Dis. 1983;148:535–542. doi: 10.1093/infdis/148.3.535
   PubMed Web of Science ®Google Scholar
• Gao LL, Yu S, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28:4445–4451. doi: 10.1016/j.vaccine.2010.03.062
   PubMed Web of Science ®Google Scholar
• Bennett AL, Smith DW, Cummins MJ, et al. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respi Viruses. 2013;7:854–862. doi: 10.1111/irv.12094
   PubMed Web of Science ®Google Scholar
• James CM, Abdad MY, Mansfield JP, et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine. 2007;25:1856–1867. doi: 10.1016/j.vaccine.2006.10.038
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Trombetti S, Soldà A, et al. Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interf Cytokine Res. 2011;31:475–479. doi: 10.1089/jir.2010.0125
   PubMed Web of Science ®Google Scholar
• Moll HP, Maier T, Zommer A, et al. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine. 2011;53:52–59. doi: 10.1016/j.cyto.2010.09.006
   PubMed Web of Science ®Google Scholar
• Dobin A, Gingeras TR. Mapping RNA-seq reads with STAR. Curr Protoc Bioinforma. 2015;51:11.14.1–19. doi: 10.1002/0471250953.bi1114s51
   PubMedGoogle Scholar
• Liao Y, Smyth GK, Shi W. The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47. doi: 10.1093/nar/gkz114
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2013. Available from: http://www.r-project.org/.
   Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:1–25. doi: 10.2202/1544-6115.1027
   PubMedGoogle Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful apporach to multiple testing. J R Stat Soc. 1995;57:289–300.
   Google Scholar
• Harper MS, Guo K, Gibbert K, et al. Interferon-α subtypes in an ex vivo model of acute HIV-1 infection: expression, potency and effector mechanisms. PLoS Pathog. 2015;11:e1005254. doi: 10.1371/journal.ppat.1005254
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Trilling M, Wagner M, et al. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-γ signaling and antiviral responses. J Exp Med. 2005;201:1543–1553. doi: 10.1084/jem.20041401
   PubMed Web of Science ®Google Scholar
• Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84–87. doi: 10.1126/science.1247005
   PubMed Web of Science ®Google Scholar
• Weinheimer VK, Becher A, Tönnies M, et al. Influenza a viruses target type II pneumocytes in the human lung. J Infect Dis. 2012;206:1685–1694. doi: 10.1093/infdis/jis455
   PubMed Web of Science ®Google Scholar
• Sato S, Li K, Kameyama T, et al. The RNA Sensor RIG-I Dually functions as an innate Sensor and direct antiviral factor for hepatitis B virus. Immunity. 2015;42:123–132. doi: 10.1016/j.immuni.2014.12.016
   PubMed Web of Science ®Google Scholar
• Weber M, Sediri H, Felgenhauer U, et al. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe. 2015;17:309–319. doi: 10.1016/j.chom.2015.01.005
   PubMed Web of Science ®Google Scholar
• Li Y, Sun B, Esser S, et al. Expression pattern of individual IFNA subtypes in chronic HIV infection. J Interf Cytokine Res. 2017;37:541–549. doi: 10.1089/jir.2017.0076
   PubMed Web of Science ®Google Scholar
• Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011;56:282–289. doi: 10.1016/j.cyto.2011.07.019
   PubMed Web of Science ®Google Scholar
• Zscheppang K, Berg J, Hedtrich S, et al. Human pulmonary 3D models For translational research. Biotechnol J. 2018;13:1700341. doi: 10.1002/biot.201700341
   PubMed Web of Science ®Google Scholar
• Hocke AC, Suttorp N, Hippenstiel S. Human lung ex vivo infection models. Cell Tissue Res. 2017;367:511–524. doi: 10.1007/s00441-016-2546-z
   PubMed Web of Science ®Google Scholar